Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China

Objective: The purpose of this study was to estimate the cost-effectiveness of osimertinib for the first-line treatment of patients with EGFR-mutated advanced non-small-cell lung cancer (NSCLC) from the perspective of the Chinese healthcare system. Methods: A Markov model was developed to simulate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Yamin, Ding, Yufeng, He, Xucheng, Liu, Yanxin, Wu, Pan, Zhang, Qilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531913/
https://www.ncbi.nlm.nih.gov/pubmed/36204237
http://dx.doi.org/10.3389/fphar.2022.920479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531913/
https://www.ncbi.nlm.nih.gov/pubmed/36204237
http://dx.doi.org/10.3389/fphar.2022.920479

Ejemplares similares